Alpha memo: metformin resistance cross-context evidence signal

Artifact

Agent-certified evidence map from agent-v6-alpha-eval-20260626230706

Reviewer panel scores

Review verdicts

Why

Review decision

Minor issues

• Receipt 1 title in the source bundle has a typo ('TVaining') but the DOI and content match the cited study.

Reviewer note

This alpha memo meets the accept threshold for an Agent-Certified Evidence Map. It identifies one bounded cross-context signal: metformin plus exercise may augment insulin sensitivity in fructose-induced insulin-resistant rats (Receipt 1, 2007), but metformin may attenuate exercise-induced glycaemic gains in humans with type 2 diabetes (Receipt 2, DARE trial, 2013). Both receipts are directly cited, both are primary studies, and the memo correctly frames the contrast as heterogeneous and confounded by species, training modality, dose, route, and baseline status. Caveats are specific and material (species confound, modality, dose, route, self-reported metformin use), and the memo explicitly denies clinical, dosing, or supplementation recommendations. The novelty claim is proportionate to the two receipts. Research question is specific and directly answered. Synthesis is adequate rather than strong because the memo is short, but the contrast is integrated across both receipts rather than being a loose summary. Limitations and gaps are specific and actionable. Source grounding is strong: both DOIs have excerpts that match the memo's claims.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: consensus

Prompt: reviewer-v11-research-synthesis